View in EDS HTML Full Text PDF Full Text

The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.

Saved in:
Bibliographic Details
Title: The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer.
Authors: Abdollahi, Angela1 (AUTHOR), Favata, Margaret1 (AUTHOR), Weber, Michael1 (AUTHOR), Roman, Valerie1 (AUTHOR), Hess, Rodrigo1 (AUTHOR), Hammond, Kayla1 (AUTHOR), Farren, Matthew R.1 (AUTHOR), Schaffer, Mike1 (AUTHOR), Gilmartin, Aidan1 (AUTHOR), Wang, Hui1 (AUTHOR), Rios-Doria, Jonathan1 (AUTHOR) jdoria@incyte.com, Amador-Arjona, Alejandro1 (AUTHOR)
Source: PLoS ONE. 8/11/2025, Vol. 20 Issue 8, p1-16. 16p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:19326203
DOI:10.1371/journal.pone.0327588